BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hemming ML, Lawlor MA, Andersen JL, Hagan T, Chipashvili O, Scott TG, Raut CP, Sicinska E, Armstrong SA, Demetri GD, Bradner JE. Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition. Cancer Res 2019;79:994-1009. [PMID: 30630822 DOI: 10.1158/0008-5472.CAN-18-1888] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Kou YW, Zhang Y, Fu YP, Wang Z. KIT and platelet-derived growth factor receptor α wild-type gastrointestinal stromal tumor associated with neurofibromatosis type 1: Two case reports. World J Clin Cases 2019; 7(24): 4398-4406 [PMID: 31911924 DOI: 10.12998/wjcc.v7.i24.4398] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Ruksha TG, Sergeeva EY, Fefelova YA, Khorzhevsky VA. [The significance of C-KIT gene mutations in the diagnosis and prognosis of malignant tumors]. Arkh Patol 2021;83:61-8. [PMID: 34278763 DOI: 10.17116/patol20218304161] [Reference Citation Analysis]
3 Bi Y, Zeng DX, Ye W, Xiao M, Yang QL, Ling Y. LncRNA PVT1 promotes cells proliferation via PI3K–AKT–mTOR Pathway in gastrointestinal stromal tumor. All Life 2021;14:136-46. [DOI: 10.1080/26895293.2021.1889685] [Reference Citation Analysis]
4 Hamdan FH, Johnsen SA. Perturbing Enhancer Activity in Cancer Therapy. Cancers (Basel) 2019;11:E634. [PMID: 31067678 DOI: 10.3390/cancers11050634] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
5 Li J, Guo S, Sun Z, Fu Y. Noncoding RNAs in Drug Resistance of Gastrointestinal Stromal Tumor. Front Cell Dev Biol 2022;10:808591. [DOI: 10.3389/fcell.2022.808591] [Reference Citation Analysis]
6 Zboril E, Yoo H, Chen L, Liu Z. Dynamic Interactions of Transcription Factors and Enhancer Reprogramming in Cancer Progression. Front Oncol 2021;11:753051. [PMID: 34616687 DOI: 10.3389/fonc.2021.753051] [Reference Citation Analysis]
7 Krishnatry AS, Voelkner A, Dhar A, Prohn M, Ferron-Brady G. Population pharmacokinetic modeling of molibresib and its active metabolites in patients with solid tumors: A semimechanistic autoinduction model. CPT Pharmacometrics Syst Pharmacol 2021;10:709-22. [PMID: 33955700 DOI: 10.1002/psp4.12639] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Horvathova Kajabova V, Soltysova A, Demkova L, Plesnikova P, Lyskova D, Furdova A, Babal P, Smolkova B. KIT Expression Is Regulated by DNA Methylation in Uveal Melanoma Tumors. Int J Mol Sci 2021;22:10748. [PMID: 34639089 DOI: 10.3390/ijms221910748] [Reference Citation Analysis]
9 Vallilas C, Sarantis P, Kyriazoglou A, Koustas E, Theocharis S, Papavassiliou AG, Karamouzis MV. Gastrointestinal Stromal Tumors (GISTs): Novel Therapeutic Strategies with Immunotherapy and Small Molecules. Int J Mol Sci 2021;22:E493. [PMID: 33419029 DOI: 10.3390/ijms22020493] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Reece AS, Hulse GK. Impacts of cannabinoid epigenetics on human development: reflections on Murphy et. al. 'cannabinoid exposure and altered DNA methylation in rat and human sperm' epigenetics 2018; 13: 1208-1221. Epigenetics 2019;14:1041-56. [PMID: 31293213 DOI: 10.1080/15592294.2019.1633868] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]